Physician profile
Mary E Holzer
NPI 1437546116
$1,406.79
in general payments reported to CMS, 2019-2025
22 companies · $83.74 in 2025
The $83.74 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.51 · 2020: $11.68 · 2022: $339 · 2023: $667 · 2024: $293 · 2025: $83.74.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,044.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,043.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $264.19 | 2022-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $241.17 | 2022-2025 | Mounjaro, Trulicity, Jardiance |
| Itamar Medical INC | $131.07 | 2023-2025 | Watchpatone |
| Idorsia Pharmaceuticals US INC | $91.05 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $81.44 | 2023-2024 | Trintellix |
| Astrazeneca Pharmaceuticals Lp | $78.78 | 2022-2024 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.85 | 2022-2024 | Tradjenta |
| Abbvie INC. | $58.82 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.78 | 2022-2023 | |
| Abbott Laboratories | $56.17 | 2023 | Freestyle Libre 3, Freestyle Libre |
| Pfizer INC. | $38.52 | 2023 | |
| Glaxosmithkline, LLC. | $34.78 | 2024 | Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $33.20 | 2025 | Inspire |
| Exact Sciences Corporation | $25.06 | 2024 | Cologuard Collection Kit |
| Genentech USA, INC. | $24.19 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $22.33 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.12 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.45 | 2022 | |
| Amgen INC. | $15.26 | 2023 | Otezla, Repatha |
| Horizon Therapeutics Plc | $14.80 | 2022 | |
| Sanofi-Aventis U.S. LLC | $14.36 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.40 | 2023 | Trulance, Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Holzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.